Business Wire1h
Daiichi Sankyo Appoints Hiroyuki Okuzawa as Chief Executive Officer
Daiichi Sankyo Company, Ltd (TSE: 4568) has appointed Hiroyuki Okuzawa, 62, to succeed Sunao Manabe, DVM, Ph.D. as Chief ...
FiercePharma2d
AZ, Daiichi's Enhertu nabs 7th FDA nod, including in 'HER2-ultralow' use, in breast cancer first
Just 11 days after AstraZeneca and Daiichi Sankyo gained FDA approval for their ... progression or death versus chemotherapy. Progression-free survival came in at a median of 13.2 months for ...
Hosted on MSN16d
Daiichi Sankyo buys solid tumour ADC from Glycotope for $132.5m
Daiichi Sankyo has finalised the acquisition of intellectual property rights for gatipotuzumab, an anti-tumour-associated ...
Business Wire17d
Daiichi Sankyo Acquires Intellectual Property Rights for Anti-TA-MUC1 Antibody in DS-3939 from Glycotope GmbH
Daiichi Sankyo Company, Ltd (TSE: 4568) announced today that it will pay Glycotope $132.5 million to acquire intellectual ...
Seeking Alpha21d
High Expectations And Data Disappointments Have Driven Daiichi Sankyo Lower
Daiichi Sankyo's stock has dropped ... and a median progression-free survival of 5.5 months and median overall survival of 11.8 months. The company has already moved forward into a Phase III ...
Enid News & Eagle18d
Daiichi Sankyo Acquires Intellectual Property Rights for Anti-TA-MUC1 Antibody in DS-3939 from Glycotope GmbH
Daiichi Sankyo Company, Ltd (TSE: 4568) announced today that it will pay Glycotope $132.5 million to acquire intellectual property rights of the anti-tumor-associated mucin-1 (TA-MUC1) antibody ...